Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Hot topics

Guidance needed on LDL lowering in very high-risk patients

Guidance needed on LDL lowering in very high-risk patients

With the advent of the PCSK9 inhibitors, reduction in LDL cholesterol levels far beyond current guideline targets is achievable. This scenario, however, has also created a quandary for clinicians. Do high and very high-risk patients at guideline-recommended goal gain additional benefit from lowering LDL cholesterol…

read more »
Adverse effects of long-term statin therapy: New statement from the EAS Consensus Panel

Adverse effects of long-term statin therapy: New statement from the EAS Consensus Panel

Clinical trials have clearly proven the efficacy and short-term safety of statin treatment. But, with people taking these medications lifelong, are there any adverse effects to consider in the longer-term? Are reports from the media about statin treatment oversensationalized and therefore skew the reporting of…

read more »
PCSK9 inhibition and neurocognitive effects:Weighing up the evidence

PCSK9 inhibition and neurocognitive effects:Weighing up the evidence

Whether lowering LDL cholesterol levels has detrimental effects on cognitive function has long been a concern with statins (1). Recently, attention has also focused on the PCSK9 inhibitors.  Professor François Mach (Geneva University Hospitals, Switzerland) discusses what is known from the latest trials. Evidence from…

read more »
Statin intolerance – 50% higher risk of recurrent heart attack in statin intolerant patients

Statin intolerance – 50% higher risk of recurrent heart attack in statin intolerant patients

Debated in the literature (1-3), statin intolerance is very much a hot topic at the moment. This new report highlights the detrimental effects on cardiovascular outcome in patients with statin intolerance. Statin-associated muscle symptoms (SAMS) are the most common clinical manifestation of statin intolerance. The…

read more »
PlayAccess to PCSK9 inhibitor treatment: NLA survey provides important pointers

Access to PCSK9 inhibitor treatment: NLA survey provides important pointers

Professor Dean G. Karalis (Director of Preventive Cardiology, Pennsylvania Hospital, USA) discusses the issues and how to counter these. FOURIER and SPIRE-2 have clearly shown the benefits of lowering LDL cholesterol beyond current targets in very high risk patients. However, from a routine practice view,…

read more »
PlayCould PCSK9 inhibitors be used in FH children?

Could PCSK9 inhibitors be used in FH children?

Prof Philip Barter gives his view.

read more »
Does PCSK9 inhibition have a role in HIV dyslipidaemia?

Does PCSK9 inhibition have a role in HIV dyslipidaemia?

With HIV (human immunodeficiency virus) patients in developed countries living longer, appropriate management of cardiovascular risk factors, notably dyslipidaemia, becomes more of an issue. But is this also the same in developing regions? As a consequence of developments in HIV management, HIV patients in developed…

read more »
Are very low LDL-C levels on a PCSK9 inhibitor safe?

Are very low LDL-C levels on a PCSK9 inhibitor safe?

One of the key concerns of clinicians is whether the very low LDL cholesterol levels attained on a PCSK9 inhibitor are safe. Such concerns have been sparked by a recent meta-analysis which suggested a signal for adverse neurocognitive effects (1). These concerns were investigated in…

read more »
FOURIER doesn’t disappoint: Amgen announces positive topline results

FOURIER doesn’t disappoint: Amgen announces positive topline results

Amgen has confirmed that the much-awaited FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial showed that treatment with the PCSK9 inhibitor evolocumab significantly reduced the risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease on optimized statin…

read more »
Bococizumab exits the PCSK9 stage: A response from PCSK9 Forum Editors

Bococizumab exits the PCSK9 stage: A response from PCSK9 Forum Editors

Pfizer announced on Tuesday, 1st November that it was discontinuing development of bococizumab, its PCSK9 inhibitor. According to the press release, the Company stated that: ‘The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering…

read more »
Optimal treatment in children with FH urgently needed!

Optimal treatment in children with FH urgently needed!

Familial hypercholesterolaemia (FH, inherited high cholesterol) is the most common inherited cause of premature coronary heart disease, affecting about 1 in 200-250 people (1). This means that worldwide, one baby is born with FH every minute. Therefore, diagnosing children with FH earlier, so that lifestyle…

read more »
Insights from Brazil: Raul Santos, InCor-University of Sao Paulo

Insights from Brazil: Raul Santos, InCor-University of Sao Paulo

The Healthcare Perspective in South America

read more »
Outcomes data are critical

Outcomes data are critical

The Healthcare System Perspective in Europe: Francois Mach, University of Geneva, Switzerland

read more »
Many key barriers are amenable to change; new strategies are needed

Many key barriers are amenable to change; new strategies are needed

General considerations: David L. Hare, University of Melbourne Australia

read more »
What prevents high risk patients gaining access to treatment with PCSK9 inhibitors?

What prevents high risk patients gaining access to treatment with PCSK9 inhibitors?

Roundtable discussion from the Fifth Closed Expert Meeting of PCSK9 Forum focused on identifying barriers to access to treatment with PCSK9 monoclonal antibody therapy, from both the patient and healthcare system perspectives. Access in developing countries is especially problematic, according to insights from South America….

read more »
No effect of PCSK9 inhibitors on new-onset diabetes

No effect of PCSK9 inhibitors on new-onset diabetes

Treatment with alirocumab for up to 18 months did not affect the incidence of new-onset diabetes, according to this pooled analysis of Phase III trials from the ODYSSEY programme.  These findings are in line with reports with evolocumab which showed no effect on glycaemic measures…

read more »
New debate on lipid screening in children and adolescents

New debate on lipid screening in children and adolescents

Experts have weighed in following publication of the US Preventive Services Task Force recommendations, which concluded that there was insufficient evidence to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents up to 20 years. To read the…

read more »
PlayNews: International Atherosclerosis Society consensus statement on severe familial hypercholesterolaemia

News: International Atherosclerosis Society consensus statement on severe familial hypercholesterolaemia

In this new statement, the International Atherosclerosis Society (IAS) has placed phenotype at the heart of management strategies for familial hypercholesterolaemia (FH, inherited high cholesterol). Commenting, lead author Dr. Raul Santos (University of São Paulo Medical School Hospital and Preventive Medicine Centre and Cardiology Program,…

read more »